It shows by animal experiments that the drug can inhibit gastric acid secretion and gastric secretion. It has obvious inhibition action to ileal contraction amplitude and frequency of animal in vivo. And it also shows favorable treatment effect for experimental gastritis model.

Paclitaxel is a new antimicrotubule antineoplactic agent. It promotes microtubule assembly, inhibits depolymerization, maintains microtubule protein stable and inhibits cells mitoses. Paclitaxel can enhance the effects of ionizing radiation in vitro, possibly by blocking cells in the G2 phase and M phase, in which cells are most radiosensitive

The drug belongs to the third-generation cephalosporin antibiotics. It has strong bactericidal activity to enterobacteria. Its minimal inhibitory concentration(MIC90) is between 0.12~0.25mg/L to bacteria as Escherichia coli, Klebsiella pneumoniae, Bacillus aerogenes, Freundii Citrobacter, Indole-positive proteus, providencia species and Serratia species.

Ceftazidime belongs to the third generation cephalosporin antibiotics. It shows a high order of antibacterial activity against Escherichia coli, Klebsiella pneumoniae, Haemophilus influenzae, Pseudomonas aeruginosa, etc. Ceftazidime also shows a good activity against nitrate-negative bacilli, bacillus alcaligenes, etc. Ceftazidime is highly stable to most beta-lactamases so it shows antibacterial activity against many drug-multiresistant strains of gram-negative bacilli mentioned above.

Cefotaxime is classified as a third generation cephalosporin and it has a wide spectrum of activity. Cefotaxime is strong active in vitro against gram-negative bacteria, as Escherichia coli, Proteus mirabilis, Klebsiella and Salmonella. Cefotaxime also has activity against Proteus and Citrobacter. Bacillus Cloaca, Bacillus aerogenes are resistant to cefotaxime.